Silence Therapeutics Income Statement (2018-2026) | SLN

Income Statement Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter) 15.70M0.76M1.50M25.30M0.14M0.20M0.16M0.03M0.42M
Cost of Revenue (Quarter) 2.80M3.33M3.64M2.04M0.05M0.09M0.06M0.01M0.01M
Gross Profit (Quarter) 12.90M-2.58M-2.14M23.27M0.09M0.14M0.10M0.02M0.41M
Operating items
Research & Development (Quarter) 6.30M7.77M20.16M-2.90M20.81M17.65M20.54M27.70M9.12M
Selling, General & Administrative (Quarter) 6.63M7.01M7.70M5.54M7.68M5.13M5.79M3.73M7.03M
Restructuring Costs (Quarter) 1.30M-0.02M
Other Operating Expenses (Quarter) -16.45M-18.64M-28.38M-20.70M
Operating Expenses (Quarter) -3.51M-3.86M27.86M2.64M0.12M3.38M26.34M31.41M16.15M
Operating Income (Quarter) -5.58M-23.39M-30.00M-4.35M-28.41M-23.96M-26.24M56.47M-15.74M
EBIT (Quarter) -5.58M-23.39M-30.00M-4.35M-28.41M-23.96M-26.24M56.47M-15.74M
Non-operating items
Other Non Operating Income (Quarter) 0.35M1.35M1.41M1.04M-3.77M-6.61M0.77M-0.02M0.57M
Net income details
EBT (Quarter) -2.07M-19.53M-35.49M12.63M-28.53M-27.34M-20.96M-12.85M-14.96M
Tax Provisions (Quarter) 0.24M0.23M0.05M0.32M0.01M0.00M
Profit After Tax (Quarter) -2.31M-19.75M-35.54M12.30M-28.53M-27.35M-20.96M-11.81M-14.96M
Income from Continuing Operations (Quarter) -2.31M-19.75M-35.54M12.30M-28.53M-27.35M-20.96M-12.85M-14.96M
Consolidated Net Income (Quarter) -2.31M-19.75M-35.54M12.30M-28.53M-27.35M-20.96M-12.85M-14.96M
Income towards Parent Company (Quarter) -2.31M-19.75M-35.54M12.30M-28.53M-27.35M-20.96M-12.85M-14.96M
Net Income towards Common Stockholders (Quarter) -2.31M-19.75M-35.54M12.30M-28.53M-27.35M-20.96M-12.85M-14.96M
Additional items
EPS (Basic) (Quarter) -0.02-0.14-0.250.09-0.20-0.19-0.15-0.09-0.11
EPS (Weighted Average and Diluted) (Quarter) -0.02-0.14-0.250.09-0.20-0.19-0.15-0.09-0.11
Shares Outstanding (Weighted Average) (Quarter) 4.57M5.04M5.50M119.91M113.29M138.11M131.88M136.05M141.20M138.75M141.68M141.70M141.69M141.69M141.70M
Shares Outstanding (Diluted Average) (Quarter) 113.29M138.11M131.88M136.05M141.20M138.75M141.68M141.69M141.70M141.69M141.70M
EBITDA (Quarter) -5.58M-23.39M-30.00M-4.35M-28.41M-23.96M-26.24M56.47M-15.74M
Tax Rate (Quarter) -11.80%-1.17%-0.14%2.57%-0.04%0.00%